<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633527</url>
  </required_header>
  <id_info>
    <org_study_id>812P202</org_study_id>
    <nct_id>NCT02633527</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD - A Double-Blind, Placebo-Controlled, Dose-Ranging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Supernus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Supernus Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      This was a randomized, double-blind, placebo-controlled, multicenter, 5-arm, parallel-group,&#xD;
      dose-ranging study to assess the efficacy and safety of SPN-812 (Viloxazine Extended-release&#xD;
      Capsule) in children 6-12 years of age with ADHD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled, multicenter, 5-arm,&#xD;
      parallel-group, dose-ranging study to assess the efficacy, safety, and tolerability of&#xD;
      SPN-812 (Viloxazine Extended-release Capsule) as monotherapy in the treatment of&#xD;
      Attention-Deficit/Hyperactivity Disorder (ADHD) in children (6-12 years of age). Subjects are&#xD;
      randomized in a 1:2:2:2:2 ratio to receive placebo or one of four active treatments (100 mg,&#xD;
      200 mg, 300 mg, or 400 mg SPN-812). The primary objective is to assess the efficacy of&#xD;
      SPN-812 in reducing ADHD symptoms as measured by the Attention-Deficit/Hyperactivity Disorder&#xD;
      Rating Scale, 4th Edition (ADHD-RS-IV).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2016</start_date>
  <completion_date type="Actual">July 25, 2016</completion_date>
  <primary_completion_date type="Actual">July 25, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Efficacy of SPN-812 on the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV)</measure>
    <time_frame>Baseline to Week 8 (End of Study)</time_frame>
    <description>The Primary Endpoint was the change from baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV) Total score at Week 8 (End of Study). The ADHD-RS-IV is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology. The scale consists of 18 items that directly correspond to the 18 Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) symptoms of ADHD. Each item is rated on a 4-point Likert-type scale from 0 (never or rarely) to 3 (very often). A Total score is calculated by adding the responses of all 18 items (range: 0-54; the higher the score, the more severe the ADHD symptoms). Lower change from baseline scores (&lt;0) represent a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of SPN-812 on Clinical Global Impression - Improvement (CGI-I) Scale</measure>
    <time_frame>Week 8 (End of Study)</time_frame>
    <description>The first additional secondary endpoint was the Clinical Global Impression-Improvement (CGI-I) Scale score at Week 8 (End of Study). The CGI-I scale is a single item assessment of how much the patient's illness has improved or worsened relative to a baseline state prior to the beginning of treatment. The CGI-I is rated on a 7-point Likert scale from 1 to 7, where 1 = &quot;Very much improved&quot;, 2 = &quot;Much improved&quot;, 3 = &quot;Minimally improved&quot;, 4 = &quot;No change&quot;, 5 = &quot;Minimally worse&quot;, 6 = &quot;Much worse&quot;, and 7 = &quot;Very much worse&quot;. Successful therapy is indicated by a lower score (&lt;4) in subsequent testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of SPN-812 on the Clinical Global Impression - Severity (CGI-S) Scale</measure>
    <time_frame>Baseline to Week 8 (End of Study)</time_frame>
    <description>The second additional secondary endpoint was the change from baseline in the Clinical Global Impression-Severity (CGI-S) Scale score at Week 8 (End of Study). The CGI-S scale is a single item clinician/investigator rating of the clinician's assessment of the severity of the ADHD symptoms in relation to the clinician's total experience with patients with ADHD. The CGI-S was rated on a 7-point Likert scale, where 1 = Normal, not at all ill, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Extremely Ill. Successful therapy is indicated by a lower CGI-S score in subsequent testing. A lower change from baseline score (&lt;0) represents a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">222</enrollment>
  <condition>Attention-Deficit/Hyperactivity Disorder (ADHD)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, qd, oral capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100mg SPN-812</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg SPN-812, qd, oral capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200mg SPN-812</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg SPN-812, qd, oral capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300mg SPN-812</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg SPN-812, qd, oral capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400mg SPN-812</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400mg SPN-812, qd, oral capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo was administered once daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100mg SPN-812</intervention_name>
    <description>100mg SPN-812 was administered once daily and compared to placebo</description>
    <arm_group_label>100mg SPN-812</arm_group_label>
    <other_name>SPN-812, Low Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200mg SPN-812</intervention_name>
    <description>200mg SPN-812 was administered once daily and compared to placebo</description>
    <arm_group_label>200mg SPN-812</arm_group_label>
    <other_name>SPN-812, Low-Medium Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>300mg SPN-812</intervention_name>
    <description>300mg SPN-812 was administered once daily and compared to placebo</description>
    <arm_group_label>300mg SPN-812</arm_group_label>
    <other_name>SPN-812, Medium-High Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>400mg SPN-812</intervention_name>
    <description>400mg SPN-812 was administered once daily and compared to placebo</description>
    <arm_group_label>400mg SPN-812</arm_group_label>
    <other_name>SPN-812, High Dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or female subjects, 6-12 years of age, inclusive, with a diagnosis of&#xD;
             ADHD according to the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM&#xD;
             IV), confirmed with the Mini International Neuropsychiatric Interview for Children and&#xD;
             Adolescents (MINI-KID).&#xD;
&#xD;
          2. ADHD-RS-IV-Parent Version: Investigator Administered and Scored score of at least 26.&#xD;
&#xD;
          3. CGI-S score of at least 4&#xD;
&#xD;
          4. Weight of at least 20 kg.&#xD;
&#xD;
          5. Free of medication for the treatment of ADHD or any psychosis for at least one week&#xD;
             prior to enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current or lifetime diagnosis of major depressive disorder, bipolar disorder,&#xD;
             personality disorder, Tourette's disorder, or psychosis not otherwise specified.&#xD;
&#xD;
          2. Currently meeting DSM-IV criteria for pervasive developmental disorder, obsessive&#xD;
             compulsive disorder, post-traumatic stress disorder, or any other anxiety disorder as&#xD;
             primary diagnosis.&#xD;
&#xD;
          3. Significant systemic disease.&#xD;
&#xD;
          4. Evidence of suicidality within the six months before Screening or at Screening.&#xD;
&#xD;
          5. BMI greater than 95th percentile for the appropriate age and gender.&#xD;
&#xD;
          6. Pregnancy or refusal to practice abstinence during the study for female subjects of&#xD;
             childbearing potential (FOCP).&#xD;
&#xD;
          7. Substance or alcohol use during the last three months.&#xD;
&#xD;
          8. Positive urine screen for cotinine, alcohol, or drugs of abuse at Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph T. Hull, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Supernus Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Clinical Research Center, LLC</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <results_first_submitted>September 29, 2021</results_first_submitted>
  <results_first_submitted_qc>September 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 27, 2021</results_first_posted>
  <disposition_first_submitted>August 11, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>August 11, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 19, 2020</disposition_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Treatment A: Placebo was administered once daily</description>
        </group>
        <group group_id="P2">
          <title>100mg SPN-812</title>
          <description>Treatment B: 100mg SPN-812 was administered once daily and compared to placebo</description>
        </group>
        <group group_id="P3">
          <title>200mg SPN-812</title>
          <description>Treatment C: 200mg SPN-812 was administered once daily and compared to placebo</description>
        </group>
        <group group_id="P4">
          <title>300mg SPN-812</title>
          <description>Treatment D: 300mg SPN-812 was administered once daily and compared to placebo</description>
        </group>
        <group group_id="P5">
          <title>400mg SPN-812</title>
          <description>Treatment E: 400mg SPN-812 was administered once daily and compared to placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Failed to meet eligibility</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Multiple reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-Treat (ITT) Population: The ITT population includes subjects who were randomized, took at least one dose of study medication, have a baseline Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV) assessment, and have at least one post-baseline ADHD-RS-IV assessment.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Treatment A: Placebo was administered once daily</description>
        </group>
        <group group_id="B2">
          <title>100mg SPN-812</title>
          <description>Treatment B: 100mg SPN-812 was administered once daily and compared to placebo</description>
        </group>
        <group group_id="B3">
          <title>200mg SPN-812</title>
          <description>Treatment C: 200mg SPN-812 was administered once daily and compared to placebo</description>
        </group>
        <group group_id="B4">
          <title>300mg SPN-812</title>
          <description>Treatment D: 300mg SPN-812 was administered once daily and compared to placebo</description>
        </group>
        <group group_id="B5">
          <title>400mg SPN-812</title>
          <description>Treatment E: 400mg SPN-812 was administered once daily and compared to placebo</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="46"/>
            <count group_id="B4" value="47"/>
            <count group_id="B5" value="44"/>
            <count group_id="B6" value="206"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.4" spread="1.89"/>
                    <measurement group_id="B2" value="8.2" spread="1.78"/>
                    <measurement group_id="B3" value="9.1" spread="1.95"/>
                    <measurement group_id="B4" value="8.9" spread="1.95"/>
                    <measurement group_id="B5" value="9.0" spread="2.18"/>
                    <measurement group_id="B6" value="8.8" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>6 to 9 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 to 12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ADHD RS-IV Total Score</title>
          <description>The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology. It consists of 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). Each item is rated on a 4-point Likert-type scale from 0 (never or rarely) to 3 (very often). Total score = sum of 18 items (range: 0 to 54). The higher the score, the more severe the ADHD symptoms (a total score &gt;=26 was an inclusion criterion of this study).</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.4" spread="7.76"/>
                    <measurement group_id="B2" value="42.4" spread="6.82"/>
                    <measurement group_id="B3" value="43.9" spread="7.45"/>
                    <measurement group_id="B4" value="41.3" spread="7.94"/>
                    <measurement group_id="B5" value="40.8" spread="7.87"/>
                    <measurement group_id="B6" value="42.1" spread="7.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ADHD RS-IV Inattention Subscale Score</title>
          <description>The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology. It consists of 18 items that correspond to 18 ADHD symptoms per DSM-IV, including 9 items for the Hyperactivity/Impulsivity (HI) subscale and 9 items for the Inattention (IA) subscale. Each item is rated on a 4-point Likert-type scale from (0=never or rarely to 3=very often). The IA Subscale score = sum of all 9 IA items on the ADHD-RS-IV (range:0 to 27). The higher the score, the more severe the IA symptoms of ADHD.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.9" spread="4.72"/>
                    <measurement group_id="B2" value="22.1" spread="3.86"/>
                    <measurement group_id="B3" value="22.2" spread="3.57"/>
                    <measurement group_id="B4" value="21.8" spread="3.75"/>
                    <measurement group_id="B5" value="21.0" spread="4.71"/>
                    <measurement group_id="B6" value="21.8" spread="4.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ADHD RS-IV Hyperactivity/ Impulsivity Subscale Score</title>
          <description>The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology. It consists of 18 items that correspond to 18 ADHD symptoms per DSM-IV, including 9 items for the Hyperactivity/Impulsivity (HI) subscale and 9 items for the Inattention (IA) subscale. Each item is rated on a 4-point Likert-type scale from (0=never or rarely to 3=very often). The HI Subscale score = sum of all 9 HI items on the ADHD-RS-IV (range:0 to 27). The higher the score, the more severe the HI symptoms of ADHD.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.5" spread="4.40"/>
                    <measurement group_id="B2" value="20.3" spread="5.15"/>
                    <measurement group_id="B3" value="21.7" spread="5.10"/>
                    <measurement group_id="B4" value="19.4" spread="5.99"/>
                    <measurement group_id="B5" value="19.7" spread="4.43"/>
                    <measurement group_id="B6" value="20.3" spread="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Efficacy of SPN-812 on the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV)</title>
        <description>The Primary Endpoint was the change from baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV) Total score at Week 8 (End of Study). The ADHD-RS-IV is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology. The scale consists of 18 items that directly correspond to the 18 Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) symptoms of ADHD. Each item is rated on a 4-point Likert-type scale from 0 (never or rarely) to 3 (very often). A Total score is calculated by adding the responses of all 18 items (range: 0-54; the higher the score, the more severe the ADHD symptoms). Lower change from baseline scores (&lt;0) represent a better outcome.</description>
        <time_frame>Baseline to Week 8 (End of Study)</time_frame>
        <population>Intent-to-Treat (ITT) Population: The ITT population includes subjects who were randomized, took at least one dose of study medication, have a baseline Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV) assessment and have at least one post-baseline ADHD-RS-IV assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Treatment A: Placebo was administered once daily</description>
          </group>
          <group group_id="O2">
            <title>100mg SPN-812</title>
            <description>Treatment B: 100mg SPN-812 was administered once daily and compared to placebo</description>
          </group>
          <group group_id="O3">
            <title>200mg SPN-812</title>
            <description>Treatment C: 200mg SPN-812 was administered once daily and compared to placebo</description>
          </group>
          <group group_id="O4">
            <title>300mg SPN-812</title>
            <description>Treatment D: 300mg SPN-812 was administered once daily and compared to placebo</description>
          </group>
          <group group_id="O5">
            <title>400mg SPN-812</title>
            <description>Treatment E: 400mg SPN-812 was administered once daily and compared to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>The Efficacy of SPN-812 on the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV)</title>
          <description>The Primary Endpoint was the change from baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV) Total score at Week 8 (End of Study). The ADHD-RS-IV is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology. The scale consists of 18 items that directly correspond to the 18 Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) symptoms of ADHD. Each item is rated on a 4-point Likert-type scale from 0 (never or rarely) to 3 (very often). A Total score is calculated by adding the responses of all 18 items (range: 0-54; the higher the score, the more severe the ADHD symptoms). Lower change from baseline scores (&lt;0) represent a better outcome.</description>
          <population>Intent-to-Treat (ITT) Population: The ITT population includes subjects who were randomized, took at least one dose of study medication, have a baseline Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV) assessment and have at least one post-baseline ADHD-RS-IV assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.5" spread="11.82"/>
                    <measurement group_id="O2" value="-16.7" spread="14.57"/>
                    <measurement group_id="O3" value="-18.4" spread="15.61"/>
                    <measurement group_id="O4" value="-18.6" spread="14.38"/>
                    <measurement group_id="O5" value="-19.0" spread="14.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0899</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.4</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0310</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.1</ci_lower_limit>
            <ci_upper_limit>-0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0268</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.3</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0209</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.8</ci_lower_limit>
            <ci_upper_limit>-1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of SPN-812 on Clinical Global Impression - Improvement (CGI-I) Scale</title>
        <description>The first additional secondary endpoint was the Clinical Global Impression-Improvement (CGI-I) Scale score at Week 8 (End of Study). The CGI-I scale is a single item assessment of how much the patient's illness has improved or worsened relative to a baseline state prior to the beginning of treatment. The CGI-I is rated on a 7-point Likert scale from 1 to 7, where 1 = &quot;Very much improved&quot;, 2 = &quot;Much improved&quot;, 3 = &quot;Minimally improved&quot;, 4 = &quot;No change&quot;, 5 = &quot;Minimally worse&quot;, 6 = &quot;Much worse&quot;, and 7 = &quot;Very much worse&quot;. Successful therapy is indicated by a lower score (&lt;4) in subsequent testing.</description>
        <time_frame>Week 8 (End of Study)</time_frame>
        <population>Intent-to-Treat (ITT) Population: The ITT population includes subjects who were randomized, took at least one dose of study medication, have a baseline Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV) assessment and have at least one post-baseline ADHD-RS-IV assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Treatment A: Placebo was administered once daily</description>
          </group>
          <group group_id="O2">
            <title>100mg SPN-812</title>
            <description>Treatment B: 100mg SPN-812 was administered once daily and compared to placebo</description>
          </group>
          <group group_id="O3">
            <title>200mg SPN-812</title>
            <description>Treatment C: 200mg SPN-812 was administered once daily and compared to placebo</description>
          </group>
          <group group_id="O4">
            <title>300mg SPN-812</title>
            <description>Treatment D: 300mg SPN-812 was administered once daily and compared to placebo</description>
          </group>
          <group group_id="O5">
            <title>400mg SPN-812</title>
            <description>Treatment E: 400mg SPN-812 was administered once daily and compared to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of SPN-812 on Clinical Global Impression - Improvement (CGI-I) Scale</title>
          <description>The first additional secondary endpoint was the Clinical Global Impression-Improvement (CGI-I) Scale score at Week 8 (End of Study). The CGI-I scale is a single item assessment of how much the patient's illness has improved or worsened relative to a baseline state prior to the beginning of treatment. The CGI-I is rated on a 7-point Likert scale from 1 to 7, where 1 = &quot;Very much improved&quot;, 2 = &quot;Much improved&quot;, 3 = &quot;Minimally improved&quot;, 4 = &quot;No change&quot;, 5 = &quot;Minimally worse&quot;, 6 = &quot;Much worse&quot;, and 7 = &quot;Very much worse&quot;. Successful therapy is indicated by a lower score (&lt;4) in subsequent testing.</description>
          <population>Intent-to-Treat (ITT) Population: The ITT population includes subjects who were randomized, took at least one dose of study medication, have a baseline Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV) assessment and have at least one post-baseline ADHD-RS-IV assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="0.88"/>
                    <measurement group_id="O2" value="2.6" spread="1.10"/>
                    <measurement group_id="O3" value="2.6" spread="1.26"/>
                    <measurement group_id="O4" value="2.2" spread="1.25"/>
                    <measurement group_id="O5" value="2.4" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1305</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1376</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0090</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0546</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of SPN-812 on the Clinical Global Impression - Severity (CGI-S) Scale</title>
        <description>The second additional secondary endpoint was the change from baseline in the Clinical Global Impression-Severity (CGI-S) Scale score at Week 8 (End of Study). The CGI-S scale is a single item clinician/investigator rating of the clinician's assessment of the severity of the ADHD symptoms in relation to the clinician's total experience with patients with ADHD. The CGI-S was rated on a 7-point Likert scale, where 1 = Normal, not at all ill, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Extremely Ill. Successful therapy is indicated by a lower CGI-S score in subsequent testing. A lower change from baseline score (&lt;0) represents a better outcome.</description>
        <time_frame>Baseline to Week 8 (End of Study)</time_frame>
        <population>Intent-to-Treat (ITT) Population: The ITT population includes subjects who were randomized, took at least one dose of study medication, have a baseline Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV) assessment and have at least one post-baseline ADHD-RS-IV assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Treatment A: Placebo was administered once daily</description>
          </group>
          <group group_id="O2">
            <title>100mg SPN-812</title>
            <description>Treatment B: 100mg SPN-812 was administered once daily and compared to placebo</description>
          </group>
          <group group_id="O3">
            <title>200mg SPN-812</title>
            <description>Treatment C: 200mg SPN-812 was administered once daily and compared to placebo</description>
          </group>
          <group group_id="O4">
            <title>300mg SPN-812</title>
            <description>Treatment D: 300mg SPN-812 was administered once daily and compared to placebo</description>
          </group>
          <group group_id="O5">
            <title>400mg SPN-812</title>
            <description>Treatment E: 400mg SPN-812 was administered once daily and compared to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of SPN-812 on the Clinical Global Impression - Severity (CGI-S) Scale</title>
          <description>The second additional secondary endpoint was the change from baseline in the Clinical Global Impression-Severity (CGI-S) Scale score at Week 8 (End of Study). The CGI-S scale is a single item clinician/investigator rating of the clinician's assessment of the severity of the ADHD symptoms in relation to the clinician's total experience with patients with ADHD. The CGI-S was rated on a 7-point Likert scale, where 1 = Normal, not at all ill, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Extremely Ill. Successful therapy is indicated by a lower CGI-S score in subsequent testing. A lower change from baseline score (&lt;0) represents a better outcome.</description>
          <population>Intent-to-Treat (ITT) Population: The ITT population includes subjects who were randomized, took at least one dose of study medication, have a baseline Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV) assessment and have at least one post-baseline ADHD-RS-IV assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.98"/>
                    <measurement group_id="O2" value="-1.4" spread="1.44"/>
                    <measurement group_id="O3" value="-1.5" spread="1.44"/>
                    <measurement group_id="O4" value="-1.6" spread="1.37"/>
                    <measurement group_id="O5" value="-1.7" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0708</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0309</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0148</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0136</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 Weeks</time_frame>
      <desc>Number of subjects is based on the Safety Population (defined as subjects who were randomized and took at least one dose of study medication)</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Treatment A: Placebo was administered once daily</description>
        </group>
        <group group_id="E2">
          <title>100mg SPN-812</title>
          <description>Treatment B: 100mg SPN-812 was administered once daily and compared to placebo</description>
        </group>
        <group group_id="E3">
          <title>200mg SPN-812</title>
          <description>Treatment C: 200mg SPN-812 was administered once daily and compared to placebo</description>
        </group>
        <group group_id="E4">
          <title>300mg SPN-812</title>
          <description>Treatment D: 300mg SPN-812 was administered once daily and compared to placebo</description>
        </group>
        <group group_id="E5">
          <title>400mg SPN-812</title>
          <description>Treatment E: 400mg SPN-812 was administered once daily and compared to placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joseph Hull, PhD, Director Clinical Research</name_or_title>
      <organization>Supernus</organization>
      <phone>240-403-5324</phone>
      <email>jhull@supernus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

